1 Abstract
Epilepsy is a complex brain disorder characterized by repetitive seizure events. Epilepsy patients often suffer from various and severe physical and psychological co-morbidities (e.g. anxiety, migraine, stroke, etc.). While general comorbidity prevalences and incidences can be estimated from epidemiological data, such an approach does not take into account that actual patient specific risks can depend on various individual factors, including medication. This motivates to develop a machine learning approach for predicting risks of future comorbidities for the individual epilepsy patient.
In this work we use inpatient and outpatient administrative health claims data of around 19,500 US epilepsy patients. We suggest a dedicated multi-modal neural network architecture (Deep personalized LOngitudinal convolutional RIsk model - DeepLORI) to predict the time dependent risk of six common comorbidities of epilepsy patients. We demonstrate superior performance of DeepLORI in a comparison with several existing methods Moreover, we show that DeepLORI based predictions can be interpreted on the level of individual patients. Using a game theoretic approach, we identify relevant features in DeepLORI models and demonstrate that model predictions are explainable in the light of existing knowledge about the disease. Finally, we validate the model on independent data from around 97,000 patients, showing good generalization and stable prediction performance over time.
Competing Interest Statement
All authors have received salaries from UCB Pharma S.A. during the runtime of this project. UCB had no influence on the scientific content of this work.
Funding Statement
All authors have received salaries from UCB Pharma S.A. during the runtime of this project. UCB had no influence on the scientific content of this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies involving human participants were reviewed and approved by UCB internal Ethics Office. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** most of the presented work has been done while the first and last author were affiliated with UCB Biosciences GmbH, Monheim
↵1 Surname changed from Gerlach to Linden in 2018
1 Surname changed from Gerlach to Linden in 2018
3 Hazard ratios computed similar to Cox proportional hazard’s model (Cox, 1972).
Data Availability
The data analyzed in this study is subject to the following licenses/restrictions: We used administrative health claims data provided by IBM Truven Health Analytics. Data access has to be requested from IBM. Requests to access these datasets should be directed to https://www.ibm.com/products/marketscan-research-databases, https://www.ibm.com/watson-health/about/truven-health-analytics .
7 Abbreviations
- AED
- Anti Epileptic Drug
- SDA
- Stacked Denoising Autoencoder
- MRMR
- Minimum Redundance Maximum Relevance
- RSF
- Random Survival Forest
